| 9.03 -1.97 (-17.91%) | 03-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.75  |
1-year : | 17.48 |
| Resists | First : | 12.63 |
Second : | 14.97 |
| Pivot price | 11.65 |
|||
| Supports | First : | 8.85 |
Second : | 7.36 |
| MAs | MA(5) : | 10.74 |
MA(20) : | 12.09 |
| MA(100) : | 18.79 |
MA(250) : | 27.28 |
|
| MACD | MACD : | -1.1 |
Signal : | -1 |
| %K %D | K(14,3) : | 7.6 |
D(3) : | 7.8 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 50.4 | Low : | 8.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LENZ ] has closed below the lower bollinger band by 22.8%. Bollinger Bands are 58.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.5 - 10.56 | 10.56 - 10.61 |
| Low: | 8.69 - 8.77 | 8.77 - 8.82 |
| Close: | 8.92 - 9.03 | 9.03 - 9.12 |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Tue, 24 Mar 2026
LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS - MarketBeat
Tue, 24 Mar 2026
LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Tue, 24 Mar 2026
LENZ: Initial VIZZ launch drove $1.6M sales and $17.5M license revenue, but net loss reached $82.1M - TradingView
Tue, 24 Mar 2026
VIZZ presbyopia launch propels LENZ Therapeutics (NASDAQ: LENZ) - Stock Titan
Tue, 24 Mar 2026
LENZ Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Tue, 24 Mar 2026
Why Lenz Therapeutics Stock Crashed Today - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 116.4 (%) |
| Shares Short | 8,430 (K) |
| Shares Short P.Month | 8,730 (K) |
| EPS | -2.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.78 |
| Profit Margin | 0 % |
| Operating Margin | -151.2 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | -28.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.55 |
| Sales Per Share | 0.55 |
| EBITDA (p.s.) | -2.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -4.39 |
| PEG Ratio | 0 |
| Price to Book value | 1.33 |
| Price to Sales | 16.14 |
| Price to Cash Flow | -6.25 |
| Dividend | 7.21 |
| Forward Dividend | 0 |
| Dividend Yield | 79.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|